04.04.12
To get ready for this year’s Parenteral Drug Association annual meeting, we spoke with a number of parenteral CMOs to gauge the state of the business, the key drivers, and how the increased regulatory burden affects operations. There was plenty of industry optimism, leavened with concerns over quality issues and client perceptions.
Milton Boyer, president of Oso Biopharmaceuticals, said, “From our perspective, we see an increase in outsourcing. That’s measured by leads, opportunities, and business we continue to sign. By those metrics, we see opportunities for CMOs.”
Stuart Hinchen, chief executive officer, president and co-founder of JHP Pharmaceuticals, was sanguine about the state of the market, noting, “The market is solid and growing. We’ve brought on seven new customers’ products over the past year and we’ve added a lot of follow-on pro
Milton Boyer, president of Oso Biopharmaceuticals, said, “From our perspective, we see an increase in outsourcing. That’s measured by leads, opportunities, and business we continue to sign. By those metrics, we see opportunities for CMOs.”
Stuart Hinchen, chief executive officer, president and co-founder of JHP Pharmaceuticals, was sanguine about the state of the market, noting, “The market is solid and growing. We’ve brought on seven new customers’ products over the past year and we’ve added a lot of follow-on pro
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
